KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Idexx Laboratories (IDXX) Shares Outstanding (Diluted Average) (2016 - 2026)

Idexx Laboratories has reported Shares Outstanding (Diluted Average) over the past 13 years, most recently at $81.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) fell 2.67% year-over-year to $81.0 million; the TTM value through Dec 2025 reached $81.0 million, down 2.67%, while the annual FY2025 figure was $81.0 million, 2.67% down from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $81.0 million at Idexx Laboratories, roughly flat from $81.2 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $86.9 million in Q1 2021 and troughed at $81.0 million in Q2 2025.
  • A 5-year average of $84.1 million and a median of $84.0 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Biggest five-year swings in Shares Outstanding (Diluted Average): rose 0.24% in 2021 and later dropped 2.88% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $86.6 million in 2021, then decreased by 2.28% to $84.6 million in 2022, then decreased by 0.74% to $84.0 million in 2023, then decreased by 0.87% to $83.2 million in 2024, then dropped by 2.67% to $81.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for IDXX at $81.0 million in Q4 2025, $81.2 million in Q3 2025, and $81.0 million in Q2 2025.